4-1BB transcriptomic expression patterns across malignancies:Implications for clinical trials of 4-1BB agonists  

作　　者：Yuji Uehara Shumei Kato Daisuke Nishizaki Hirotaka Miyashita Suzanna Lee Mary K.Nesline Sarabjot Pabla Jeffrey M.Conroy Paul DePietro Heidi Ko Jason K.Sicklick Razelle Kurzrock 

机构地区：[1]Department of Thoracic Oncology and Respiratory Medicine,Tokyo Metropolitan Cancer and Infectious Diseases Center,Komagome Hospital,Tokyo,Japan [2]Department of Precision Cancer Medicine,Center for Innovative Cancer Treatment,Tokyo Medical and Dental University,Tokyo,Japan [3]Center for Personalized Cancer Therapy and Division of Hematology and Oncology,Department of Medicine,University of California San Diego,Moores Cancer Center,La Jolla,California,United States [4]Dartmouth Cancer Center,Hematology and Medical Oncology,Lebanon,New Hampshire,United States [5]Labcorp Oncology,Durham,North Carolina,United States [6]OmniSeq Incorporation,Buffalo,New York,United States [7]Division of Surgical Oncology,Department of Surgery,Center for Personalized Cancer Therapy,University of California San Diego,La Jolla,California,United States [8]Medical College of Wisconsin Cancer Center and Genomic Sciences and Precision Medicine Center,Medical College of Wisconsin,Milwaukee,Wisconsin,United States [9]Department of Oncology,Medical College of Wisconsin Cancer Center,Milwaukee,Wisconsin,United States [10]Department of Oncology,University of Nebraska,Omaha,Nebraska,United States

出　　处：《Cancer Communications》2024年第10期1168-1172,共5页癌症通讯（英文）

基　　金：funded in part by the National Institutes of Health(grant numbers:5U01CA180888-08 and 5UG1CA233198-05.)。

摘　　要：4-1BB,a member of the tumor necrosis factor receptor superfamily,is an important co-stimulatory molecule regulating the activity of immune cells across a range of physiological and pathological processes,which culminates in a potent immune response(Figure 1A and B)[1,2].Numerous clinical trials have been conducted utilizing 4–1BB agonists(Supplemental Table S1);however,previous and ongoing 4-1BB agonist trials are being conducted without biomarker selection,which potentially explains their modest efficacy.Interestingly,several studies suggest the potential value of utilizing transcriptomics in addition to genomics to identify the unique immunologic signature of individual tumors[3–7].

关 键 词：clinical utilizing FIGURE 

分 类 号：R73[医药卫生—肿瘤]